Serapha Bio to Go Public via Merger with Boundless Bio, Raising $230 Million
Boundless Bio and Serapha Bio announce a merger and $230 million private placement. The combined company will advance SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).